Unique case of macular edema following rituximab treatment for antibody‐mediated rejection in kidney transplant recipient

Uveitis Associated with Cancer Immunotherapy: Long-Term Outcomes

“…The inner and outer layers were more rarely involved (case 1) [45]. ME has been previously reported in patients treated with rituximab [57][58][59]. An association between ibrutinib, Bruton tyrosine kinase inhibitor, and macular edema has been previously reported [56].…”

“…Most of the reported cases had anterior uveitis, as in the case series of 22 CIT-associated uveitis reported by Whilst et al in which half of the patients had anterior uveitis [8,16,[34][35][36][37][38][39][40]. Posterior segment inflammation showed various aspects, and most of them are summarized in table 3 [41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59]. Serous retinal detachment suggesting VKH-like disease has been reported with the use of anti-CTLA-4 treatment [41,42] and nivolumab combined with antiBRAF [11,46].…”

Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature

“…1 ME is a rare consequence of Rituximab infusions and very few cases are reported in the literature. [3][4][5] Details on previous cases described are summarized in Table 1. Usually, ME occurs a few weeks after infusions and can be successfully managed with oral, subtenon or intravitreal steroids.…”

“…Usually, ME occurs a few weeks after infusions and can be successfully managed with oral, subtenon or intravitreal steroids. [3][4][5] Although there is a published case of monocular subretinal fluid in a patient with orbital IgG4-RD, 6 the onset of vision loss shortly after Rituximab infusion, the bilaterality and the absence of an orbital localization of the IgG4-RD, led us to consider the ME as a Rituximab side effect. However, albeit the temporal association of Rituximab infusion and ME points toward Rituximab as a cause for ME, bilaterality has not been uniformly reported in the past cases of ME secondary to Rituximab.…”

“…However, albeit the temporal association of Rituximab infusion and ME points toward Rituximab as a cause for ME, bilaterality has not been uniformly reported in the past cases of ME secondary to Rituximab. [3][4][5] Considering the inflammatory pattern on FA and the resolution after IDI, the ME secondary to Rituximab is likely to be related to a local release of cytokines after infusions. We know that IDI is an "invasive" option for the treatment of inflammatory ME.…”